Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142520
Corporate User License Price USD 6000
Corporate User License Price INR 427560
Site License Price USD 4000
Site License Price INR 285040
Request a Quote

Report Title

Alcoholic Hepatitis-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Alcoholic Hepatitis-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Alcoholic Hepatitis-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Alcoholic Hepatitis-Pipeline Review, H2 2017



Executive Summary

Alcoholic Hepatitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis-Pipeline Review, H2 2017, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alcoholic Hepatitis-Overview

Alcoholic Hepatitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcoholic Hepatitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcoholic Hepatitis-Companies Involved in Therapeutics Development

Alfact Innovation

Generon (Shanghai) Corp Ltd

Gilead Sciences Inc

GRI Bio Inc

Immuron Ltd

Intercept Pharmaceuticals Inc

Promethera Biosciences SA

Verlyx Pharma Inc

Vital Therapies Inc

Alcoholic Hepatitis-Drug Profiles

ALF-5755-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-652-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRI-0621-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentamidine isethionate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKM-02GI1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcoholic Hepatitis-Dormant Projects

Alcoholic Hepatitis-Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis

May 23, 2016: Vital Therapies Enrolls First Subject in VTL-308

Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Alcoholic Hepatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Alcoholic Hepatitis-Pipeline by Alfact Innovation, H2 2017

Alcoholic Hepatitis-Pipeline by Generon (Shanghai) Corp Ltd, H2 2017

Alcoholic Hepatitis-Pipeline by Gilead Sciences Inc, H2 2017

Alcoholic Hepatitis-Pipeline by GRI Bio Inc, H2 2017

Alcoholic Hepatitis-Pipeline by Immuron Ltd, H2 2017

Alcoholic Hepatitis-Pipeline by Intercept Pharmaceuticals Inc, H2 2017

Alcoholic Hepatitis-Pipeline by Promethera Biosciences SA, H2 2017

Alcoholic Hepatitis-Pipeline by Verlyx Pharma Inc, H2 2017

Alcoholic Hepatitis-Pipeline by Vital Therapies Inc, H2 2017

Alcoholic Hepatitis-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Alfact Innovation

Generon (Shanghai) Corp Ltd

Gilead Sciences Inc

GRI Bio Inc

Immuron Ltd

Intercept Pharmaceuticals Inc

Promethera Biosciences SA

Verlyx Pharma Inc

Vital Therapies Inc

Alcoholic Hepatitis Therapeutic Products under Development, Key Players in Alcoholic Hepatitis Therapeutics, Alcoholic Hepatitis Pipeline Overview, Alcoholic Hepatitis Pipeline, Alcoholic Hepatitis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person